Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 2,360,000 shares, a decline of 33.9% from the October 31st total of 3,570,000 shares. Based on an average daily volume of 22,220,000 shares, the short-interest ratio is currently 0.1 days.

Insider Buying and Selling at Conduit Pharmaceuticals

In related news, major shareholder Ltd Nirland sold 939,009 shares of Conduit Pharmaceuticals stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.10, for a total value of $93,900.90. Following the sale, the insider now owns 6,092,000 shares of the company’s stock, valued at approximately $609,200. The trade was a 13.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 3,658,000 shares of company stock worth $386,136. Insiders own 34.74% of the company’s stock.

Conduit Pharmaceuticals Trading Up 8.0 %

CDT stock traded up $0.01 during midday trading on Friday, reaching $0.11. 9,347,975 shares of the company’s stock traded hands, compared to its average volume of 37,767,360. The company has a 50-day moving average price of $0.11 and a two-hundred day moving average price of $0.68. Conduit Pharmaceuticals has a 52 week low of $0.08 and a 52 week high of $7.83.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.